These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9065921)

  • 21. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
    Köberle D; Thürlimann B
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):169-76. PubMed ID: 12113022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches.
    Nobert GS; Kraak MM; Crawford S
    Bull Cancer; 2006 Jul; 93(7):E59-66. PubMed ID: 16873071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary experience with pure antiestrogens.
    Howell A
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4369s-4375s; discussion 4411s-4412s. PubMed ID: 11916227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
    Dunn BK; Ford LG
    Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant endocrine therapy in postmenopausal breast cancer.
    Ingle JN
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):480S-5S. PubMed ID: 12538504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiestrogen treatment of breast cancer: an overview.
    Pearson OH; Manni A; Arafah BM
    Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twenty years of systemic therapy for breast cancer.
    Mina L; Sledge GW
    Oncology (Williston Park); 2006 Jan; 20(1):25-32; discussion 32-3, 36, 40. PubMed ID: 16572592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer.
    Rutqvist LE; Johansson H;
    Acta Oncol; 2007; 46(2):133-45. PubMed ID: 17453361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
    Buzdar AU
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of endometrial cancer in asymptomatic postmenopausal breast cancer patient treated with tamoxifen: a case report.
    Sinawat S; Chiyabutra T; Kleabkaew P
    J Med Assoc Thai; 2001 Jul; 84(7):1033-6. PubMed ID: 11759963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
    Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
    Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W; Santen RJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.